{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:39:16Z","timestamp":1789007956859,"version":"build-2803163510"},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To study the efficacy and safety of anti-CD52 antibody (alemtuzumab) in the treatment of refractory and relapsing Beh\u00e7et disease (BD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Thirty-two patients (22 women) with BD received 60 courses of alemtuzumab between 1994 and 2013. Three-dose regimens were used: 134 mg in 21 courses (Group 1), 95 mg in 18 courses (Group 2), and 60 mg in 21 courses (Group 3). Immunosuppressive drugs were stopped at the time of alemtuzumab, and prednisolone was reduced according to clinical response. Treatment response was assessed by clinical status, inflammatory activity, prednisolone dose, and the need for subsequent immunosuppressive drugs and disease relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>After the first alemtuzumab course, 27 of 32 patients (84%) achieved partial or complete remission (CR). Fifty of 60 courses (83%) resulted in remission (66% CR) without differences in remission rates between dosing regimens. Profound lymphocyte depletion occurred after all courses. Relapse-free survival rates were 83.6% at 6 months and 52.8% at 12 months, and were higher among Group 1 patients (Group 1: 100% and 77.8%, Group 2: 81.3% and 37.5%, and Group 3: 65.0% and 37.1%, p &lt; 0.001). Mild to moderate infusion reactions occurred after 16 courses (27%). Eight patients (25%) developed symptomatic thyroid disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Alemtuzumab led to remission in the majority of patients with difficult-to-treat BD. Relapse was common and may be associated with lower dosing. Adverse events included infusion reactions and new autoimmunity. Achieving complete lymphocyte depletion did not affect the remission rate or duration.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.141344","type":"journal-article","created":{"date-parts":[[2015,8,15]],"date-time":"2015-08-15T19:58:42Z","timestamp":1439668722000},"page":"1906-1913","source":"Crossref","is-referenced-by-count":51,"title":["Alemtuzumab as Remission Induction Therapy in Beh\u00e7et Disease: A 20-year Experience"],"prefix":"10.3899","volume":"42","author":[{"given":"Aladdin J.","family":"Mohammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok W.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afzal N.","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.W.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2015,8,15]]},"reference":[{"key":"2018112909351352000_42.10.1906.1","first-page":"1078","article-title":"International Study Group for Beh\u00e7et\u2019s Disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"2018112909351352000_42.10.1906.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.11.996"},{"key":"2018112909351352000_42.10.1906.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.24642"},{"key":"2018112909351352000_42.10.1906.4","first-page":"588","article-title":"Increased peripheral blood gamma delta+ T cells and natural killer cells in Beh\u00e7et\u2019s disease","volume":"19","author":"Suzuki","year":"1992","journal-title":"J Rheumatol"},{"key":"2018112909351352000_42.10.1906.5","first-page":"506","article-title":"Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Beh\u00e7et\u2019s disease\u2014a multicenter study. The Beh\u00e7et\u2019s Disease Research Committee of Japan","volume":"16","year":"1989","journal-title":"J Rheumatol"},{"key":"2018112909351352000_42.10.1906.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-005-0612-z"},{"key":"2018112909351352000_42.10.1906.7","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2133.1995.tb16946.x","article-title":"Immunohistology of skin pathergy reaction in Beh\u00e7et\u2019s disease","volume":"132","author":"G\u00fcl","year":"1995","journal-title":"Br J Dermatol"},{"key":"2018112909351352000_42.10.1906.8","first-page":"189","article-title":"Immunohistology of oral lesions from patients with recurrent oral ulcers and Beh\u00e7et\u2019s syndrome","volume":"78","author":"Poulter","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"2018112909351352000_42.10.1906.9","doi-asserted-by":"publisher","DOI":"10.1080\/030097402320318387"},{"key":"2018112909351352000_42.10.1906.10","first-page":"329","article-title":"Divergent cytokine production profile in Beh\u00e7et\u2019s disease. Altered Th1\/Th2 cell cytokine pattern","volume":"25","author":"Raziuddin","year":"1998","journal-title":"J Rheumatol"},{"key":"2018112909351352000_42.10.1906.11","doi-asserted-by":"publisher","DOI":"10.1080\/03009740600905380"},{"key":"2018112909351352000_42.10.1906.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2835-8"},{"key":"2018112909351352000_42.10.1906.13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"2018112909351352000_42.10.1906.14","first-page":"455","article-title":"[Immunosuppressive therapy of Behcet\u2019s syndrome. Long term follow-up evaluation (author\u2019s transl)]","volume":"4","author":"Bonnet","year":"1981","journal-title":"J Fr Ophtalmol"},{"key":"2018112909351352000_42.10.1906.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301926"},{"key":"2018112909351352000_42.10.1906.16","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12178"},{"key":"2018112909351352000_42.10.1906.17","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90759-A"},{"key":"2018112909351352000_42.10.1906.18","first-page":"473","article-title":"Refractory Wegener\u2019s granulomatosis: a model for shorter immunotherapy of autoimmune diseases","volume":"32","author":"Lockwood","year":"1998","journal-title":"J R Coll Physicians Lond"},{"key":"2018112909351352000_42.10.1906.19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.4.751"},{"key":"2018112909351352000_42.10.1906.20","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.1.107"},{"key":"2018112909351352000_42.10.1906.21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg424"},{"key":"2018112909351352000_42.10.1906.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem034"},{"key":"2018112909351352000_42.10.1906.23","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2003.037192"},{"issue":"Suppl 72","key":"2018112909351352000_42.10.1906.24","first-page":"S62","article-title":"Switching of anti-TNF-\u03b1 agents in Beh\u00e7et\u2019s disease","volume":"30","author":"Furuta","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909351352000_42.10.1906.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802670"},{"key":"2018112909351352000_42.10.1906.26","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1343797"},{"key":"2018112909351352000_42.10.1906.27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2201"},{"key":"2018112909351352000_42.10.1906.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.081661"},{"key":"2018112909351352000_42.10.1906.29","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-307042"},{"key":"2018112909351352000_42.10.1906.30","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318284735c"},{"key":"2018112909351352000_42.10.1906.31","unstructured":"National Health Service . Service specification and standards \u2013 Be\u00e7het\u2019s syndrome service, 2012. [Internet. Accessed June 25, 2015.] Available from: www.webarchive.org.uk\/wayback\/archive\/20130325152307\/ http:\/\/www.specialisedservices.nhs.uk\/document\/10502"},{"key":"2018112909351352000_42.10.1906.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.34583"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.141344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:59:04Z","timestamp":1543499944000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.141344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,15]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,1]]},"published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.3899\/jrheum.141344"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.141344","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,15]]}}}